Emmanuel Guardiola

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 149 citations

Medicine, Gynecology, Oncology +15

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer

Emmanuel Guardiola, Frédéric Peyrade, L. Chaigneau et al. · European Journal of Cancer · 2004 · 118 citations

Medicine, Oncology, Chemotherapy +4

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Michail Ignatiadis, Saskia Litière, Françoise Rothé et al. · Annals of Oncology · 2018 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17